MARKET OUTLOOK The Crohn’s disease (CD) therapy market will continue to evolve over the next decade. The well-established tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., Janssen/Merck’s…
MARKET OUTLOOK The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population,…
Patients with osteoporosis and osteopenia are at increased risk of suffering fractures. These fractures place a considerable burden on public health systems, and significant unmet need remains in…
Acute coronary syndrome (ACS)─an umbrella term that encompasses acute ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina─is a leading cause of…
The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12 and -23…
The hepatitis C virus (HCV) therapy market has been marked by tremendous growth, and the treatment landscape has undergone a rapid evolution with the launch of novel direct-acting antivirals (DAAs…
Abstract: Owing to the large diagnosed prevalent population, relatively high rates of drug treatment across patients of all disease severities, and high rates of polypharmacy—particularly among…
Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population…
The schizophrenia therapy market is mature and very crowded given the presence of numerous atypical and typical antipsychotic agents, including the continued genericization of key oral therapies,…
The renal anemia market will expand over our 2016-2026 study period, fueled by increasing prevalence and a high unmet need for drugs that can effectively, safely, and conveniently control the…
Obesity is a significant public health concern in the major pharmaceutical markets under study and is growing into an epidemic. Despite the prevalence of the disease, few drugs are available to…
The maturing but highly lucrative market for MSDMTs continues to fragment as new entrants propel ongoing shifts in a complicated treatment algorithm. Roche/Genentech’s Ocrevus will intensify…
Decision Resources Group anticipates the next ten years to be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to grow. Existing agents fail to…
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL…
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The newly marketed oritavancin (The Medicine…
